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In an attempt to differentiate an allergic patch test 
response from an irritant response, we evaluated by 
flow cytometry the percentages of various epidermal 
cell populations isolated from allergen and irritant-
treated patch test sites. Nine allergic individuals were 
patch tested with various allergens (Rhus, dinitro-
chlorobenzene [DNCB], or nickel chloride) and a ve-
hicle control for 48 h. Eight additional individuals 
were patch tested with irritating chemicals (sodium 
lauryl sulfate or nonanoic acid) and with a vehicle con-
trol for 48 h. Epidermal cells, isolated from suction 
blisters, were double labeled for CD1/HLA-DR, 
CD3/HLA-DR, or CD36/HLA-DR cell surface 
markers and analyzed by flow cytometry to determine 
the percentage of various cell populations. A mean in-
crease of 0.91 ± 0.3 in the percentage of DR+CD1+ 
Langerhans cells over the vehicle control patch test site 
was detected in allergen-positive patch test sites in al-
lergic individuals, whereas a decrease of 0.19 ± 0.2 in 
the percentage of DR +CD 1 + Langerhans cells from the 
W ith increasing understanding of the ce.1lular and molecular events of contact sensitivity [1-4], investigators have attempted to de-velop improved methods for differentially diagnosing contact allergic reactions from 
contact· irritant reactions in humans. Most studies have investigated 
Langerhans cells, T cells, and macrophages to determine differences 
in structure and phenotypic expression of markers in contact allergic 
reactions [5 - 9]. In addition, the diagnostic relevance of the pres-
ence of the HLA-DR antigen on keratinocytes has also been exam-
ined in humans [10,11]. These studies have attempted to distinguish 
between allergic and irritant reactions to patch tests by using semi-
quantitative histologic examination of skin biopsies. In general, the 
results of comparative studies have shown, at best, only modest 
qualitative differences between allergic and irritant reactions 
[5 ,7,8,10 - 12]. More recently, Baadsgaard et at [13] showed that, 
after epicutaneous challenge with allergens, the number of 
CDl +DR+ epidermal Langerhans cells increased in a time-depen-
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vehicle control patch test site was detected in irritant-
treated patch test sites. Epidermal cells from allergen-
positive patch test sites also exhibited an increase of 
S.2 ± 1.8 in percentage ofDR+CD1- cells over the ve-
hicle control patch test site compared to an increase 
change of 0.8 ± 0.4 in epidermal cells isolated from 
irritant-treated patch test sites. We also found that DR + 
cells that lacked the CD1 determinant expressed the 
macrophage/monocyte antigen CD36 (OKMS). Fi-
nally, a 2.3 ± 0.8 increase in the percentage of 
DR-CD3+ cells over the vehicle control patch test site 
was observed in allergen-positive patch test sites com-
pared to an increase of 0.2 ± 0.2 observed in irritant-
treated patch test sites. These results demonstrate a sig-
nificant increase in DR+CD1+, DR+CD1-CD36+, and 
DR-CD3+ epidermal cells in allergen-positive patch 
test sites compared to irritant patch test sites. Key words: 
Langerhans cells/cotltact setlsitization. ] Invest Dermatol 
103:524-529,1994 
dent way and, concomitantly, CDI-0KM5+DR+ epidermal (l1on-
Langerhans) cells appeared. N o comparison was made with known 
contact irritants. 
In this study, we demonstrate that after epicutaneous treatment 
with allergens the number of Langerhans cells increased and, con-
comitantly, T cells and a DR+CDI- CD36{OKM5)+ cell popula-
tion appeared. The results show that flow cytometry analysis of 
suction blister-derived epidermal cells is useful in evaluating aller-
gic and irritant human patch-test responses. 
MATERIALS AND METHODS 
Subjects and Test Materials (Table I) Sixteen healthy volunteers, live 
male and 11 female, between the ages of 25 and 60 years (mean 42) partici-
pated in this study. Nine of the subjects had a history of contact allergy to one 
of the selected test allergens. Subjects were patched on the volar forearm 
w ith 200 JlI of the test material and a vehicle control, using 19-mm Parke-
Davis Professional Medical Products patches (patch area of 3.61 cm2) . After 
48 h, the patches were removed and the test sites scored. Eight- or 10-mm 
suction blisters were raised on the test and vehicle control sites using a 
Dermovac device ([nstrumentarium OY, Espoo, Finland) [14] . Allergens 
used were poison ivy/ oak extract (rhus, 1 : 50 w /v in ethanol stock solution; 
Hollister Stier, Spokane, WA), nickel sulfate (Omniderm, [nc., Montreal, 
Canada), nickel chloride (Sigma C hemical Co., St. Louis, MO), and 1-
chloro-2, 4-dinitrochloro benzene (DN CB; Sigma). Irritants used were so-
0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 
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Table I. Test Material Dose and Vehicle, and Number of Subjects Patch Tested 
Dose per 
Patch T est Unit Area Number of 
Test Material Concentration Vehicle (jLg/ cm2) Subjects 
Poison ivy/oak mix 
(Rhus) 
1:50,000 50% ethanol in PBS 1.11" 4 
Nickel sul fate 
Nickel chloride 
5% Petrolatum 2770 1 
2.5% Petrolatum 1385 2 
2.5% Distilled H2O 1385 1 
DNCB 
SLS 
0.05% Acetone:olive oil (4 : 1) 27.7 1 
0.25% PBS 138.5 2 
0.5% PBS 277 1 
1.0% PBS 554 2 
N onanoic acid 13.9% (v/v, 1-Propanol 6925 3 
0.9 g/ml) 
"Supplied as a 1 : 50 (W IV ) solution diluted 1 : 1000 in 50% ethanol in PBS. 
dium lauryl sul fa te (SLS; Fisher Scientific; Pittsburgh, PAl and nonanoic 
acid (grade I, Sigma). 
Epidermal C ell Suspension Preparation and Staining Single-cell 
suspensions were prepared by incubation of suction blister roofs (epidermal 
sheets) in 0.5% trypsin (Gibco, Grand Island, NY) in phosphate-buffered 
sal ine (PBS; Gibco) for 30 min at 37"C followed by disaggregation in 0.05% 
DNAase (Sigma) in Hanks' balanced salt solution (HBSS; Gibco). Cells were 
filtered through 100 Jim nylon mesh to obtain a single-cell suspension. Cells 
were washed and resuspended in fluorescence-activated cell sorter (FACS) 
buffer (calcium- and magnesium-free HBSS with 2% heat-inactivated feta l 
bovine serum (Gibco), 0.01 % DNAase (Sigma), and 0.2% disodium ethy-
lenediaminetetraacetic acid (EDTA, Sigma). The cell suspensions were 
counted and percent viability determined by trypan blue exclusion. Cells 
were double labeled with anti-HLA-DR-phycoerythrin (PE) cOlyugate 
(Ortho Diagnostics, Raritan, NJ) and either anti-OKT6-fluorescein iso-
thiocyanate (FITC) conjugate (COl ; Ortho), anti-OKT3-FITC conjugate 
(CD3; Ortho), or anti - OKM5-FITC cOlyugate (CD36; Ortho). Appropri-
a te isotype FITC and PE controls (Ortho) were included. The cells were 
incubated with antibodies for 45 min at 4 dC, washed once, and resuspended 
in FACS buffer for analysis. 
Flow Cytometry Analysis Stained cell suspensions were analyzed using 
a Coulter Model 753 flow cytometer and Elite Data Analysis software 
(Coulter Electronics, Hialeah, FL). Dead cells were omitted from analysis 
using a forward angle light scatter (FALS) versus 90 · light scatter (LS) gate 
established by backgating on cells that excluded propidium iodide (PI) (see 
Live Cell Gate in (Fig 1). The FALS discriminator was adjusted to eliminate 
debris smaller than lymphocytes. A population of lymphocytes, purified 
from human peripheral blood, was analyzed to establish a FALS versus 90 · 
LS gate, which was used in the analysis of suspensions labeled for DR and 
CD3 markers (see Lymphocyte Gate in Fig 1). The CD36+ gate represents the 
FALS and 90· LS pattern of all live cells that were backgated as HLA-
DR+CD36+ from an aJIergic individual. The CD36+ gate was used to set the 
CD36+ threshold level in isotype controls. Analysis thresholds were set so 
that FITC and PE isotype controls contained less than 1 % positive staining 
cells. Reproducibility of results from experiment to experiment was ensured 
by running calibration beads and adjusting gains, high voltages and compen-
sations to meet target values. Immuno-Brite Level II fluorospheres (Coulter) 
were used for HLA-DR versus COl calibration. Flow Cytometry Standards 
Co. (San Jaun, PRJ high PE 820 beads and low FITC 821co custom com-
pensation beads were used for HLA-DR versus CD3. At least 50,000 events 
were analyzed per sample so that even for the small populations (e.g., 
CD1+DR+Langerhans cells) approximately 1000 events were recorded. In 
addition, we performed an experiment to examine the reproducibility of the 
flow cytometry technique by performing multiple analyses of a single sam-
ple. We found that an average Langerhans cel l number (DR+CD1+) of 
3.24% with an SE of 0.08 was obtained following eight multiple analyses of 
the same sample. Histograms were analyzed to determine percentages of 
Langerhans cell (DR+CD1 +),lymphocyte (DR- CD3+), and DR+CD1 - cell 
populations. 
Statistical Analysis For statistical analysis, the percent vehicle control 
patch test values were subtracted from the percentage of their corresponding 
allergen- or irritant-treated patch test sites. The resulting changes observed 
in the cell population percentages in the allergen- and irritant-treated patch 
test sites were compared and analyzed for significant differences. IfBartietr's 
test of homogeneity of variance was not significant, then samples were 
analyzed using a t test. If Bartlett's test was significant, then the samples were 
compared usmg a t test WIth Satterthwaite's approximation [15]. Differences 
were considered statistically significant if p ::5 0.05. 
RESULTS 
Clinical Severity Mter Allergen and Irritant Treatment An 
attempt was made to choose concentrations of both the irritants and 
aller gens th at would give similar clinical reactions. For the most 
part , we were successful in choosing concentrations that yielded 
mild to moderate reactions for both the irritants and allergens tested 
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Figure 1. Flow cytometry epidermal cell analysis gate and nonsense 
Ab controls. 0) FALS versus 90 · LS gates; b) dual parameter histogram of 
isotype FITC and PE controls for HLA-DR versus COl analysis; c) single 
parameter histogram of the isotype CD3 control sample derived from the 
dual parameter analysis of HLA-DR and CD3. T he FALS versus 90 · LS 
lymphocyte gate was used to eliminate autofluorescence and nonspecific 
antibody staining from other ce ll types. d) Dual parameter histogram of the 
isotype control sample for analysis ofHLA-DR and CD36. The FALS versus 
90 · LS CD36 gate was used to eliminate autofluorescence and nonspecific 
antibody stain ing from the other cel l types. 
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Table II. Patch Test Scores and Flow Cytometry Results· 
Allergen Patch Test Data 
Allergen Vehicle 
Subject Score! 
Treatment Test/Vehicle %DR+CD1+ %DR+CD1- %DR-CD3+ %DR+CD1+ %DR+CD1 - %DR- CD3+ 
1 : 50,000 RHUS 2/1 5.1 8.6 8.4 2.4 1.6 1.8 
1 : 50,000 RHUS 2/0 1.5 2.9 6.4 0.8 0.9 NO' 
1 : 50,000 RHUS 1/0 1.6 5.2 3.0 1.5 1.3 0.6 
1 : 50,000 RHUS 2/1 3.7 9.1 4.0 2.6 1.6 0.6 
0.05% DNCB 2EP/0 2.7 18.4 4.1 0.9 0.6 0.2 
5% NiS04 lE/l 0.6 3.4 1.0 0.5 0.3 0.4 
2.5% NiCI 1/0 0.9 0.7 0.2 1.3 0.1 0.0 
2.5% NiCI 2EPW/0 2.9 4.8 1.4 1.0 0.3 0.5 
2.5% NiCI 2EPS/0 0.9 0.9 0.3 0.7 0.2 0.1 
Mean ±SEM 2.2 ± 0.5 6.0 ± 1.8 3.2 ± 0.9 1.3 ± 0.3 0.8 ± 0.2 0.5 ± 0.2 
Irritant Patch Test Data 
Irritant Vehicle 
Subject Score! 
Treatment Test/Vehicle %DR+CD1+ %DR+CD1- %DR- CD3+ %DR+CD1+ %DR+CD1- %DR- CD3+ 
0.25% SLS 1/0 0.6 0.2 0.5 0.9 0.2 1.1 
0.5% SLS 1/0 0.4 0.3 0.2 1.1 0.9 0.3 
0.25% SLS 1/0 2.4 1.7 0.7 2.0 0.9 0.6 
1.0% SLS 2/0 1.5 3.4 0.8 1.8 2.5 1.0 
1.0% SLS 2/0 2.5 3.2 1.2 1.4 0.2 0.2 
13.9% Non A 2/1 0.8 0.6 0.3 1.5 0.1 0.1 
13.9% Non A 2/0 0.4 1.5 0.9 0.9 0.2 0.0 
13.9% Non A 2/0 1.0 0.6 0.0 1.5 0.3 0.1 
Mean ±SEM 1.2 ± 0.3 1.4 ± 0.4 0.6 ± 0.1 1.4 ± 0.4 0.8 ± 0.3 0.4 ± 0.2 
• Percentage of DR+CDl+, DR+CD I- , and DR-CD3+ cells in the epidermis of allergen-, irritant- and vehicle-treated skin were determined using now cytometry analysis of 
suction blister-derived cells at 48 h . 
• Scores: 0, no visible erythemia; 1, mild erythema; 2, moderate erythema. E, edema; P, papules; W, weeping; S, spreading. 
( Not determined. 
(Table II). Most reactions obtained were characterized by mild to 
moderate erythema. However, as expected, some four of nine of the 
allergen-induced responses also exhibited edema, papules, weeping, 
or spreading. 
Allergen- and Irritant-Induced Changes in Epidermal 
DR +CDl + Langerhans Cells Because it had been demonstrated 
previously that vehicle treatment (e.g., petrolatum occlusion) can 
cause changes in Langerhans cell number [13,16]' we compared all 
test results with vehicle controls instead of untreated skin. Repre-
sentative flow cytometry histograms illustrating DR+CD1+ Lan-
gerhans cell s from allergen-, irritant-, and vehicle control-treated 
patch test sites are shown in Fig 2. Individual percent values for 
allergen-, irritant-, and vehicle-treated patch test sites are tabulated 
in Table II. The mean percent of Langerhans cells in allergen- and 
irritant-treated patch test sites was 2.2 ± 0.5 (n = 9) and 1.2 ± 0.3 
(n = 8), respectively (Table II). The mean percent of Langerhans 
cell s for the irritant and allergen vehicle control values was 1.4 ± 
0.4 and 1.3 ± 0.3, respectively. Five of the eight irritant patched 
subjects demonstrated a decrease in the percent of Langerhans cells 
compared to their vehicle controls. In addition, no increased ex-
pression of class II antigen, as determined by fluorescence intensity 
of the HLA-DR label, was observed in either treatment group (data 
not shown). To further examine changes in the Langerhans cell 
population in allergen and irritant patch-tested skin, the difference 
in the percentage of Langerhans cells in test treatment from vehicle 
control treatment was determined. A mean increase of 0.9 ± 0.3 in 
the percentage of DR+CD1+ Langerhans cells from the vehicle 
control patch test site was detected in allergen-positive patch test 
sites in allergic individuals, whereas a decrease of 0.2 ± 0.2 in the 
percentage of DR+CD 1 + Langerhans cells from the vehicle control 
patch test sites was detected in irritant-treated patch test sites (Fig 
3a). The slight increase in the percent of Langerhans cells detected 
in allergen-treated patch test sites was significantly different from 
the change detected in irritant-treated patch test sites (p s; 0.02). 
Allergic Reactions Induce the Appearance of Epidermal 
DR+CDI-CD36+ Cells Allergic reactions also demonstrated 
the emergence of a DR+CDl- cel l population at 48 h. Flow cytom-
etry histograms illustrating this DR+CDl- cell population in aller-
gen-, irritant-, and vehicle-treated patch test sites are shown in Fig 
2. The individual percent values for each a1lergen-, irritant-, and 
vehicle-treated patch test site are given in Table II. The mean 
percent DR+CDl- cells was greater in allergen-patched subj ects 
(6.0 ± 1.8; n = 9) than that observed in irritant-patched subj ects 
(1.4 ± 0.4; n = 8). The mean percent DR+CDl- cells in irritant-
and allergen-vehicle-tested subjects was 0.8 ± 0.3 and 0.8 ± 0.2, 
respectively. All allergen-patched subjects (nine of nine) demon-
strated at least a three-fold or greater increase in the percentage of 
DR+CDl- cells compared to their corresponding vehicle control, 
whereas only three of eight irritant-treated subj ects demonstrated a 
three-fold or greater increase. To further analyze this DR+CDl-
cell population, we determined the difference in the percentage of 
cells in the test treatment from the vehicle control treatment. A 
5.2 ± 1.8 increase in the percentage of DR+CDl- cells was de-
tected in allergen-patched subjects compared to an increase of 
0.8 ± 0.4 change observed in irritant-patched subjects (Fig 3b). 
The increase in the percentage ofDR+CDl- cells detected in the 
allergen-patched subjects was significantly different from the 
change detected in the irritant-treated subjects (p s; 0.04). 
We found that DR + cells that lacked the CD 1 determinant 
expressed the macrophage/monocyte antigen CD36 (Fig 4, 
Table ill). The HLA-DR+CD36+ cells in the allergen-tested sam-
ple back gate entirely into the CD36 FALS versus the 90° LS re-
gion (see Fig la) and correlate with the percentage of cells 
in the HLA-DR+CDl- region (see Table III). Also, the percent 
of DR+CDl- epidermal cell s (8.4%) was very similar to the per-
cent of DR+CD36+ cells (9.1 %) obtained from a DNCB allergen-
patched subject. These results suggest that these DR+CDl- epi-
dermal cells are macrophages/monocytes, not DR+ keratino-
cytes. 
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Figure 2. Flow eytometry histograms. HLA-DR versus COl and single 
CD3 for epidermal cell preparations taken from a) vehicle control, b) irri-
tant-treated, or c) allergen-treated sites. These samples represent the average 
responses listed in Table II for the various treatments. 
Allergic Reactions Induce the Appearance of Epidermal 
DR- CD3+ T Cells The appearance of DR-CD3+ T cells was 
demonstrated at 48 h in the epidermis of allergen-patched subjects. 
No DR+CD3+ cells were found in any of the samples tested (data 
not shown). Flow cytometry histograms illustrating this DR -CD3+ 
cell population in allergen-, irritant-, and vehicle-patched subjects 
are shown in Fig 2. The individual percent values for each allergen-, 
irritant-, and vehicle-patched subject are given in Table n. The 
mean percentage of DR-CD3+ T cells was greater in allergen-
patched subjects (3.2 ± 0.9; n = 9) than that observed in irritant-
patched subjects (0.6 ± 0.1; n = 8). The mean percentage of 
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Figure 4. DR+ cells, which lack the CDl determinant, express the 
macrophage/monocyte antigen CD36 in allergen-treated patch-test 
sites. Analysis of HLA-DR and CD36 antigens in epidermal cel l prepara-
tions from (a) vehicle control and (b) allergen patch-tested site of the same 
individual. The histograms were gated using the live ce ll gate to show the 
complete pattern. 
DR-CD3+ T cells in the irritant- and allergen-vehicle-patched 
subjects was 0.4 ± 0.2 and 0.5 ± 0.2, respectively . To further ana-
lyze the appearance of the DR- CD3+ cell population, we deter-
mined the difference in the percentage of cells of the test treatment 
from the vehicle control. A 2.3 ± 0.8 increase in the percentage of 
DR-CD3+ cells was detected in allergen-patched subjects com-
pared to an increase of 0.2 ± 0.2 detected in irritant-patched sub-
jects (Fig 3c) . The increase in DR-CD3+ T cells detected in 
allergen-patch - tested subjects was significantly different from the 
change detected in irritant-patch - tested subjects (p :s; 0.03). 
DISCUSSION 
Consistent with previous reports [8,9,13 ,1 7], we observed a slight 
increase in the percentage of DR+CD1 + Langerhans cells in aller-
gen-patched subjects 48 h after allergen application. Similar to our 
findings, Baadsgaard et af [13], using immunostaining of suction 
blister-derived epidermal cells and fluorescence microscopy, 
showed that the percentage of DR+CD1+ Langerhans cells in-
creased in a time-dependent manner. The Langerhans cell percent-
age on day 7 from vehicle-treated sites was 2.2 ± 0.06 compared to 
3.7 ± 1.4 for the allergen sites. The increase in the percentage of 
Langerhans cells was less dramatic on days 1,3, and 4. The authors 
did not, however, evaluate epidermal changes in irritant-tested sub-
jects. In studies comparing Langerhans cell changes in irritant- and 
allergen-treated subjects, varied results have been obtained. Avn-
storp et af [7] and Kanerva et af [12] reported that the number of 
Langerhans cells in the epidermis was unchanged in both allergic 
and irritant reactions. In contrast, Gawkrodger et af [8] reported that 
the number of Langerhans cells in the epidermis was almost halved 
at 48 h in the irritant reaction, but Langerhans cell counts were 
increased by a third between 24 and 48 h of the allergic response. 
a) DR+CDl+ 
3.0 " ---------
b) DR+CD1-
" ~----~....:...----- - - -..., 
----, 
c) CD3+DR-
. -------
g 2.' ~ 
., ' .0 j 5 l 
.! 1.I .....j 
~ to ~ 
! 0.' 
li 0.0 +-----'---------------1 
~ 
~ ·0 .5 
il .1.0 -'-_______ ---' 
ALLBROBN la.RITANT 
TJlUIATM8HT 
10 ::::-
- .. ~ I ~ *-
2 -
~ 0 -----!--j Q 
., 
ALL SMOBN 
;;: J 
- 7 .J 
.. J ~ I -
• "1 
~ J 
~ 3 j 
.:: 2 ~ .-
, 
, 
5 0 -lj-------''-----
TR RATMnNT 
I 
Figure 3. Significant increases in DR+CD1+, DR+CD1-, and DR -CD3+ epidermal cells in allergen- versus irritant-treated sites. a) The change 
in percentage ofDR+CDl + Langerhans cells in allergen patch-tested sites was significantly different from the irritant-tested sites (p :s; 0.02). b) The increase in 
DR+CD1- cells in allergen-tested subjects was significantly greater (p:s; 0.04) than the change detected in irritant-tested subjects. c) DR- CD3+ T-lympho-
eyte changes observed in allergen-tested sites were significantly different (p :s; 0 .03) from the irritant-tested group. Solid diamolld, individual test values minus 
vehicle control; /iIlC, mean value; asterisk, mean values arc significantly different. 
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Table III. CD36 Expression on Epidermal Cells from DNCB-Treated Subject" 
Treatment 
0.0125% DNCE 
Vehicle (acetone: olive oil) 
4.4 
2.6 
8.4 
0.3 
9.1 
0.7 
4.5 
2.3 
• Percentage of DR+C D1 +, DR+CD1- , and DR+CD36+ ce lls in the epidermis of ONCB patch-tested ski n were determined using now cytomctry analysis of suction blisrer-
derived cel ls at 48 h. 
We observed a decrease in the percentage of Langerhans cel ls in five 
of eight irritant-treated subjects (Table II). Ferguson et al [5] have 
reported that Langerhans cells in the epidermis (per mm inner epi-
dermal length) were usually greatly reduced in irritant reactions but 
remained within normal limits in allergic reactions. 
Enk and Katz [18,19] have demonstrated in mice that contact 
allergens modulate the expression of MHC class II on epidermal 
Langerhans cel ls. In our studies, increased MHC Class II expression 
was not observed in humans in either allergen- or irritant-treated 
subjects when using flow cytometry analysis (data not shown) . It is 
important to note, however, that we were examining C lass II 
changes during the elicitation phase of a pre-existing contact al-
lergy, compared to Enk and Katz, who examined the induction 
phase of contact sensitizati~n.. . 
We did observe a sig11lficant IJ1crease IJ1 the percentage of 
DR+CDl- cells in allergen-patched skin compared to irritant- and 
vehicle-patched skin. Baadsgaard et af [13] have demonstrated pre-
viously the appearance of DR+CDl- cells in allergen-treated skin, 
as well as characterizing the cells by demonstrating their expression 
of the macrophage/monocyte antigen CD36 (OKMS). The au-
thors, using immunostaining of suction blister-derived epidermal 
cells and fluorescence microscopy, showed that the number of 
DR+CD1-CD36+ cells increased in a time-dependent manner fol-
lowing epicutaneous treatment with allergen. Moreover, the num-
ber of DR+CDl-: epidermal cells was equal to the number of 
DR+CD36+(OKMS). We found the DR+CD1 - cells to be distinct 
from Langerhan cells in that 1) they were smaller, as determined by 
flow cytometry, 2) they lacked the COl marker, and 3) they ex-
pressed CD36. 
The appearance of DR+CDl- epidermal cel ls in allergen-
patched sk in was much more dramatic than that observed in irri-
tant-patched skin . In a study examining epidermal changes follow-
ing patch testing with irritants, Lisby et al [20] showed that there 
was a time-dependent decrease in the percentage of Langer hans cells 
and, concomitantly, an induction of DR+ epidermal cells that also 
expressed the macrophage/monocyte antigen CD36(OKMS). The 
authors observed an approximate 0.5 - 1 (n = 7) increase in the per-
centage of DR+CD36(OKMS)+ cells fo llowing the application of 
the irritants, SLS, or croton oil, whereas we observed an increase of 
0.7 ± 0.4 (n = 8) in the percentage fo llowing application of SLS 
and nonanoic acid. Again, a greater increase in percentage was ob-
served following allergen treatment (5.2 ± 1.8). The function of 
DR+CD1- epidermal cel ls in allergic and irritant reactions is un-
known. Baadsgaard et al [13] have speculated that these cells may 
function to downregulate immune responses. Moreover, this cell 
type may be analogous to the DR+CDI - CD36+ antigen-presenting 
cells that appear in human skin in response to certain wavelengths of 
ultraviolet radiation and that have been shown to activate suppres-
sor T -cell pathways [21 - 23]. Cooper et af [24] have shown that the 
relation between Langerhans cell depletion and the appearance of 
DR+CD1- macrophages is accompanied by a significant down mo-
dulatory effect on the ability of humans to generate a T-cell -
mediated response to contact allergens through irradiated skin. 
Thus, these cell s, which appear in greater frequency in allergic than 
in irritant responses, may represent a negative feedback mechanism 
down-regulating the inflammatory reaction in contact dermatitis. 
As one would expect, T cells have been noted in allergic reactions 
[8,9,17] . Wood et al [9] showed that T cells were present in each of 
eight biopsies isolated from subjects treated epicutaneously with 
allergens. In five biopsies, the minority ofT cells were HLA-DR+. 
We did not observe any HLA-DR+CD3+ T cells in either irritant-
or all ergic-treated subjects. Gawkrodger et al [8] showed that 
CD4(Leu 3a) T cells were greater in irritant (dithranol) reactions 
than in allergic (nickel) reactions at 48 h. A few investigators have 
found no differences between irritant and all ergic infiltrates in re-
gard to T cell s [7,10,12,25] . The difference in our findings may be 
due to the techniques used (blister versus biopsy method) or the type 
of irritants used. Regardless, further studies wi ll be needed with 
more irritants and allergens to determine whether T-cell infiltra-
tion will be usefu l as a specific marker of allergic responses when 
using flow cytometry analysis of suction blister-derived epidermal 
cells. 
Typically, allergic contact dermatitis reactions that present in a 
classical manner (e.g. erythema, edema, vesiculation , spreading, 
etc.), persist for a number of days, can be reproduced easily on a 
naive site, and are not difficult to interpret as having an allergic 
basis. However, reactions that lack one or more of these characteris-
tics can be quite difficult to interpret as being allergic or irritant in 
nature. Therefore, we have been interested in developing better 
approaches to evaluating these equivocal reactions, specifically , less 
severe reactions that exhibit only erythema and edema. The results 
of our studies suggest that flow cytometry analysis of suction blis-
ter-derived epidermal cell s may be a useful approach for evaluating 
human all ergic and irritant patch test responses, especially when 
responses are mild to moderate in nature. To better evaluate this 
approach, further analysis of subjects treated with additional all er-
gens and irritants will be needed to assess the usefulness of this 
technology for differential diagnosis of human sensitization re-
sponses. 
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